Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia

Ashok Srinivasan, John C. Panetta, Shane J. Cross, Asha Pillai, Brandon M. Triplett, David R. Shook, Mari H. Dallas, Christine Hartford, Anusha Sunkara, Guolian Kang, Jeffrey Jacobsen, John Choi, Wing Leung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The safety, pharmacokinetics, and biological effect of plerixafor in children as part of a conditioning regimen for chemo-sensitization in allogeneic hematopoietic stem cell transplantation (HSCT) have not been studied. This is a phase I study of plerixafor designed to evaluate its tolerability at dose of .24 mg/kg given intravenously on day -4 (level 1); day -4 and day -3 (level 2); or day -4, day -3, and day -2 (level 3) in combination with fludarabine, thiotepa, melphalan, and rabbit antithymocytic globulin for a second allogeneic HSCT in children with refractory or relapsed leukemia. Immunophenotype analysis was performed on blood and bone marrow before and after plerixafor administration. Twelve patients were enrolled. Plerixafor at all 3 levels was well tolerated without dose-limiting toxicity. Transient gastrointestinal side effects of National Cancer Institute-grade 1 or 2 in severity were the most common adverse events. The area under the concentration-time curve increased proportionally to the dose level. Plerixafor clearance was higher in males and increased linearly with body weight and glomerular filtration rate. The clearance decreased and the elimination half-life increased significantly from dose level 1 to 3 (P < .001). Biologically, the proportion of CXCR4+ blasts and lymphocytes both in the bone marrow and peripheral blood increased after plerixafor administration.

Original languageEnglish (US)
Pages (from-to)1224-1228
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number8
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Leukemia
Pharmacokinetics
Safety
Bone Marrow
Thiotepa
Melphalan
National Cancer Institute (U.S.)
Globulins
Glomerular Filtration Rate
Half-Life
JM 3100
Body Weight
Lymphocytes
Rabbits

Keywords

  • Allogeneic
  • Children
  • Plerixafor
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia. / Srinivasan, Ashok; Panetta, John C.; Cross, Shane J.; Pillai, Asha; Triplett, Brandon M.; Shook, David R.; Dallas, Mari H.; Hartford, Christine; Sunkara, Anusha; Kang, Guolian; Jacobsen, Jeffrey; Choi, John; Leung, Wing.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 8, 01.01.2014, p. 1224-1228.

Research output: Contribution to journalArticle

Srinivasan, A, Panetta, JC, Cross, SJ, Pillai, A, Triplett, BM, Shook, DR, Dallas, MH, Hartford, C, Sunkara, A, Kang, G, Jacobsen, J, Choi, J & Leung, W 2014, 'Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia', Biology of Blood and Marrow Transplantation, vol. 20, no. 8, pp. 1224-1228. https://doi.org/10.1016/j.bbmt.2014.04.020
Srinivasan, Ashok ; Panetta, John C. ; Cross, Shane J. ; Pillai, Asha ; Triplett, Brandon M. ; Shook, David R. ; Dallas, Mari H. ; Hartford, Christine ; Sunkara, Anusha ; Kang, Guolian ; Jacobsen, Jeffrey ; Choi, John ; Leung, Wing. / Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 8. pp. 1224-1228.
@article{426cff0656fe4d18b8d0126b782273fd,
title = "Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia",
abstract = "The safety, pharmacokinetics, and biological effect of plerixafor in children as part of a conditioning regimen for chemo-sensitization in allogeneic hematopoietic stem cell transplantation (HSCT) have not been studied. This is a phase I study of plerixafor designed to evaluate its tolerability at dose of .24 mg/kg given intravenously on day -4 (level 1); day -4 and day -3 (level 2); or day -4, day -3, and day -2 (level 3) in combination with fludarabine, thiotepa, melphalan, and rabbit antithymocytic globulin for a second allogeneic HSCT in children with refractory or relapsed leukemia. Immunophenotype analysis was performed on blood and bone marrow before and after plerixafor administration. Twelve patients were enrolled. Plerixafor at all 3 levels was well tolerated without dose-limiting toxicity. Transient gastrointestinal side effects of National Cancer Institute-grade 1 or 2 in severity were the most common adverse events. The area under the concentration-time curve increased proportionally to the dose level. Plerixafor clearance was higher in males and increased linearly with body weight and glomerular filtration rate. The clearance decreased and the elimination half-life increased significantly from dose level 1 to 3 (P < .001). Biologically, the proportion of CXCR4+ blasts and lymphocytes both in the bone marrow and peripheral blood increased after plerixafor administration.",
keywords = "Allogeneic, Children, Plerixafor, Stem cell transplantation",
author = "Ashok Srinivasan and Panetta, {John C.} and Cross, {Shane J.} and Asha Pillai and Triplett, {Brandon M.} and Shook, {David R.} and Dallas, {Mari H.} and Christine Hartford and Anusha Sunkara and Guolian Kang and Jeffrey Jacobsen and John Choi and Wing Leung",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2014.04.020",
language = "English (US)",
volume = "20",
pages = "1224--1228",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia

AU - Srinivasan, Ashok

AU - Panetta, John C.

AU - Cross, Shane J.

AU - Pillai, Asha

AU - Triplett, Brandon M.

AU - Shook, David R.

AU - Dallas, Mari H.

AU - Hartford, Christine

AU - Sunkara, Anusha

AU - Kang, Guolian

AU - Jacobsen, Jeffrey

AU - Choi, John

AU - Leung, Wing

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The safety, pharmacokinetics, and biological effect of plerixafor in children as part of a conditioning regimen for chemo-sensitization in allogeneic hematopoietic stem cell transplantation (HSCT) have not been studied. This is a phase I study of plerixafor designed to evaluate its tolerability at dose of .24 mg/kg given intravenously on day -4 (level 1); day -4 and day -3 (level 2); or day -4, day -3, and day -2 (level 3) in combination with fludarabine, thiotepa, melphalan, and rabbit antithymocytic globulin for a second allogeneic HSCT in children with refractory or relapsed leukemia. Immunophenotype analysis was performed on blood and bone marrow before and after plerixafor administration. Twelve patients were enrolled. Plerixafor at all 3 levels was well tolerated without dose-limiting toxicity. Transient gastrointestinal side effects of National Cancer Institute-grade 1 or 2 in severity were the most common adverse events. The area under the concentration-time curve increased proportionally to the dose level. Plerixafor clearance was higher in males and increased linearly with body weight and glomerular filtration rate. The clearance decreased and the elimination half-life increased significantly from dose level 1 to 3 (P < .001). Biologically, the proportion of CXCR4+ blasts and lymphocytes both in the bone marrow and peripheral blood increased after plerixafor administration.

AB - The safety, pharmacokinetics, and biological effect of plerixafor in children as part of a conditioning regimen for chemo-sensitization in allogeneic hematopoietic stem cell transplantation (HSCT) have not been studied. This is a phase I study of plerixafor designed to evaluate its tolerability at dose of .24 mg/kg given intravenously on day -4 (level 1); day -4 and day -3 (level 2); or day -4, day -3, and day -2 (level 3) in combination with fludarabine, thiotepa, melphalan, and rabbit antithymocytic globulin for a second allogeneic HSCT in children with refractory or relapsed leukemia. Immunophenotype analysis was performed on blood and bone marrow before and after plerixafor administration. Twelve patients were enrolled. Plerixafor at all 3 levels was well tolerated without dose-limiting toxicity. Transient gastrointestinal side effects of National Cancer Institute-grade 1 or 2 in severity were the most common adverse events. The area under the concentration-time curve increased proportionally to the dose level. Plerixafor clearance was higher in males and increased linearly with body weight and glomerular filtration rate. The clearance decreased and the elimination half-life increased significantly from dose level 1 to 3 (P < .001). Biologically, the proportion of CXCR4+ blasts and lymphocytes both in the bone marrow and peripheral blood increased after plerixafor administration.

KW - Allogeneic

KW - Children

KW - Plerixafor

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84904057587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904057587&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.04.020

DO - 10.1016/j.bbmt.2014.04.020

M3 - Article

C2 - 24769325

AN - SCOPUS:84904057587

VL - 20

SP - 1224

EP - 1228

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -